Natixis Investment Managers International Takes Position in Progyny, Inc. (NASDAQ:PGNY)

Natixis Investment Managers International acquired a new stake in Progyny, Inc. (NASDAQ:PGNY) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,058 shares of the company’s stock, valued at approximately $117,000.

Several other large investors also recently modified their holdings of PGNY. Vanguard Group Inc. raised its position in shares of Progyny by 7.4% in the third quarter. Vanguard Group Inc. now owns 8,157,604 shares of the company’s stock valued at $277,522,000 after purchasing an additional 565,160 shares during the period. Pacer Advisors Inc. raised its position in shares of Progyny by 148.7% in the fourth quarter. Pacer Advisors Inc. now owns 17,254 shares of the company’s stock valued at $642,000 after purchasing an additional 10,317 shares during the period. Fort Washington Investment Advisors Inc. OH raised its position in shares of Progyny by 58.1% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 688,020 shares of the company’s stock valued at $25,581,000 after purchasing an additional 252,910 shares during the period. Deepwater Asset Management LLC raised its position in shares of Progyny by 2.0% in the fourth quarter. Deepwater Asset Management LLC now owns 316,892 shares of the company’s stock valued at $11,782,000 after purchasing an additional 6,149 shares during the period. Finally, Trust Point Inc. bought a new position in shares of Progyny in the fourth quarter valued at about $510,000. 94.93% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Barclays decreased their price target on shares of Progyny from $48.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, May 13th. Canaccord Genuity Group decreased their price target on shares of Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. JMP Securities assumed coverage on shares of Progyny in a research note on Tuesday, July 16th. They issued an “outperform” rating and a $36.00 price target on the stock. Truist Financial decreased their price target on shares of Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a research note on Friday, May 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $48.00 price target on shares of Progyny in a research note on Thursday, May 16th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.40.

Insider Activity

In other news, President Michael E. Sturmer sold 4,515 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $31.95, for a total value of $144,254.25. Following the sale, the president now directly owns 380,038 shares in the company, valued at approximately $12,142,214.10. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, President Michael E. Sturmer sold 9,030 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $30.00, for a total value of $270,900.00. Following the completion of the transaction, the president now owns 362,583 shares in the company, valued at approximately $10,877,490. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, President Michael E. Sturmer sold 4,515 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $31.95, for a total transaction of $144,254.25. Following the completion of the transaction, the president now owns 380,038 shares of the company’s stock, valued at approximately $12,142,214.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 15,007 shares of company stock worth $456,660. Corporate insiders own 12.30% of the company’s stock.

Progyny Trading Up 2.2 %

Progyny stock traded up $0.62 during trading hours on Thursday, reaching $28.60. 743,474 shares of the stock were exchanged, compared to its average volume of 958,553. The stock has a 50 day moving average of $27.60 and a two-hundred day moving average of $33.11. Progyny, Inc. has a twelve month low of $23.90 and a twelve month high of $44.95. The company has a market cap of $2.72 billion, a P/E ratio of 46.89, a price-to-earnings-growth ratio of 1.83 and a beta of 1.46.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, May 9th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Progyny had a net margin of 5.53% and a return on equity of 11.61%. The company had revenue of $278.08 million for the quarter, compared to the consensus estimate of $289.41 million. During the same period last year, the company posted $0.18 EPS. The firm’s quarterly revenue was up 7.6% compared to the same quarter last year. On average, analysts expect that Progyny, Inc. will post 0.73 earnings per share for the current fiscal year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.